Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676365 | 0.88 | ADORA2A (0.52) | KMT2AMEN1ALDH1A1HSD17B10NPC1 | |
| SCHEMBL3677098 | 0.87 | ADORA3 (0.51) | KMT2AMEN1ALDH1A1HSD17B10NPC1 | |
| SCHEMBL3677616 | 0.76 | ADORA2A (0.61) | KMT2AMEN1ALDH1A1HSD17B10MAPT | |
| SCHEMBL3676034 | 0.76 | ADORA2A (0.61) | KMT2AMEN1ALDH1A1HSD17B10MAPT | |
| SCHEMBL3676192 | 0.76 | ADORA2A (0.61) | KMT2AMEN1ALDH1A1HSD17B10MAPT | |
| SCHEMBL3674966 | 0.75 | ADORA2A (0.60) | KMT2AMEN1ALDH1A1HSD17B10MAPT | |
| SCHEMBL3675006 | 0.72 | ADORA2A (0.54) | KMT2AMEN1ALDH1A1HSD17B10MAPT | |
| SCHEMBL1256441 | 0.68 | KMT2A (0.63) | KMT2AMEN1ALDH1A1HSD17B10NPC1 | |
| SCHEMBL3675033 | 0.66 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL1255496 | 0.66 | L3MBTL1 (0.75) | KMT2AMEN1ALDH1A1HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | disclosed |
| EP-1349861-B1 | THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | HIF1AN, HIF1A, EGLN3 | KMT2A 1072/4885MEN1 4004/4885ALDH1A1 1375/4885 |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | CHRNA5, HTR5A, CHRNA6 | KMT2A 3114/4885MEN1 4870/4885ALDH1A1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.